Federal Court delists Regeneron patent, clearing path for Amgen biosimilar launch
The Federal Court has ruled that a patent for the treatment of age-related macular degeneration (AMD) owned by New York-based Regeneron Pharmaceuticals is ineligible for inclusion on the patent register, clearing...To view the full article, register now.
Already a subscriber? Click here to view full article